In vitro effects of a recombinant toxin targeted to the fibroblast growth factor receptor on rat vascular smooth muscle and endothelial cells.
- 1 September 1992
- journal article
- abstracts
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 71 (3) , 640-645
- https://doi.org/10.1161/01.res.71.3.640
Abstract
The dominant mechanism responsible for restenosis after angioplasty is believed to be the activation of medial smooth muscle cells (SMCs), leading to their proliferation, migration to the subintima, and further proliferation. To develop novel strategies that might inhibit or prevent restenosis, we previously used a chimeric toxin composed of transforming growth factor-alpha (which targets the epidermal growth factor receptor) and mutated Pseudomonas exotoxin to preferentially recognize and kill rapidly proliferating, versus quiescent, vascular SMCs. We have recently cloned and expressed a recombinant gene encoding Pseudomonas exotoxin with a mutated (nonfunctional) cell recognition domain fused with the ligand acidic fibroblast growth factor, termed aFGF-PE66(4Glu)KDEL; thus, this recombinant toxin targets the fibroblast growth factor receptor. In the present study, we evaluated the relative effects of this chimeric toxin on quiescent versus rapidly proliferating vascular SMCs and also determined whether aFGF-PE66(4Glu)KDEL exerted different effects on SMCs versus endothelial cells. Rapidly proliferating SMCs (grown in 10% fetal bovine serum) were very sensitive to the cytotoxic effects of aFGF-PE66(4Glu)KDEL, whereas cytotoxicity was significantly less when the SMCs were in a quiescent state (grown in medium supplemented with 0.5% fetal bovine serum). The chimeric toxin was also significantly less cytotoxic against endothelial cells. Competition studies using excess acidic fibroblast growth factor indicated that the cytotoxic effects are specifically mediated by the fibroblast growth factor receptor. Thus, the present studies suggest a potentially expanded role of recombinant toxin therapy in restenosis: multiple receptors can be targeted, and cytotoxic effects, at least in vitro, can be preferentially directed to rapidly proliferating vascular SMCs, with relative sparing of vascular endothelial cells.(ABSTRACT TRUNCATED AT 250 WORDS)Keywords
This publication has 33 references indexed in Scilit:
- Rational design of a chimeric toxin: an intramolecular location for the insertion of transforming growth factor .alpha. within Pseudomonas exotoxin as a targeting ligandBioconjugate Chemistry, 1992
- Culture‐induced increase in acidic and basic fibroblast growth factor activities and their association with the nuclei of vascular endothelial and smooth muscle cellsJournal of Cellular Physiology, 1991
- Angioscopic observation of the coronary luminal changes induced by percutaneous transluminal coronary angioplastyAmerican Heart Journal, 1989
- Long-Term Follow-up after Percutaneous Transluminal Coronary AngioplastyNew England Journal of Medicine, 1987
- Functional domains of pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coliCell, 1987
- Inducible interleukin-1 gene expression in human vascular smooth muscle cells.Journal of Clinical Investigation, 1986
- Coronary arterial findings after accidental death immediately after successful percutaneous transluminal coronary angioplastyThe American Journal of Cardiology, 1985
- Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplastyJournal of the American College of Cardiology, 1985
- Restenosis after percutaneous transluminal coronary angioplasty (PTCA): A report from the PTCA registry of the national heart, lung, and blood instituteThe American Journal of Cardiology, 1984
- Cultured endothelial cells produce heparinlike inhibitor of smooth muscle cell growthThe Journal of cell biology, 1981